Peptide-based in vivo delivery agents for oligonucleotides and siRNA

Nucleic Acid Therapeutics

Volumn 22, Issue 2, 2012, Pages 71-76

  Coursindel, Thibault ^a   Järver, Peter ^a   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETEPLIRSEN; LIPOPEPTIDE; MORPHOLINO OLIGONUCLEOTIDE; NANOCARRIER; NANOVECTOR; OLIGONUCLEOTIDE; PENETRATIN; PEPTIDE DERIVATIVE; PEPTIDE NUCLEIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG SAFETY; EXON; HUMAN; IN VIVO STUDY; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; LIPOPEPTIDES; MOLECULAR SEQUENCE DATA; NANOPARTICLES; OLIGONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84859501273     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0341     Document Type: Review

References (46)

1. ALLINQUANT, B., HANTRAYE, P., MAILLEUX, P., MOYA, K., BOUILLOT, C., and PROCHIANTZ, A. (1995). Down-regulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 128, 919-927.
2. ALVAREZ-ERVITI, L., SEOW, Y., YIN, H., BETTS, C., LAKHAL, S., and WOOD M.J.A. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotech. 29, 341-345.
3. BONGARTZ, J.P., AUBERTIN, A.M., MILHAUD, P.G., and LEBLEU, B. (1994). Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22, 4681-4688.
4. BURRER, R., NEUMAN, B.W., TING, J.P.C., STEIN, D.A., MOULTON, H.M., IVERSEN, P.L., KUHN, P., and BUCH-MEIER, M.J. (2007). Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 81, 5637-5648.
5. CIRAK, S., ARECHAVALA-GOMEZA, V., GUGLIERI, M., FENG, L., TORELLI, S., ANTHONY, K., ABBS, S., GARRALDA, M.E., BOURKE, J., WELLS, D.J., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open label, phase 2, dose-escalation study. Lancet 378, 595-605.
6. CROMBEZ, L., MORRIS, M.C., DUFORT, S., ALDRIAN-HERRADA, G., NGUYEN, T., MCMASTER, G., COLL, J.-L., HEITZ, F., and DIVITA G. (2009). Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37, 4559-4569.
7. DEAS, T.S., BENNETT, C.J., JONES, S.A., TILGNER, M., REN, P., BEHR, M.J., STEIN, D.A., IVERSEN, P.L., KRAMER, L.D., BERNARD, K.A., et al. (2007). In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrobial Agents Chemother. 51, 2470-2482.
8. DIVITA, G., HEITZ, F., MORRIS, M.C., and ALDRIAN-HERRADA, G. (2009). Cell-penetrating peptides for intracellular delivery of molecules. U. S. Patent Application 2009/0156503.
9. DU, L., KAYALI, R., C. B., FIKE, F., HU, H., IVERSEN, P.L., and GATTI, R.A. (2011). Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum. Mol. Gen. 20, 3151-3160.
10. EL ANDALOUSSI, S., LEHTO, T., MÄGER, I., ROSENTH-ALAIZMAN, K., OPREA, I.I., SIMONSON, O.E., SORK, H., EZZAT, K., COPOLOVICI, D.-M., KURRIKOFF, K., et al. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39, 3972-3987.
11. EZZAT, K., EL ANDALOUSSI, S., ABDO, R., and LANGEL, U. (2010). Peptide-based matrices as drug delivery vehicles. Curr. Pharm. Design 16, 1167-1178.
12. EZZAT, K., ELANDALOUSSI, S.,ZAGHLOUL, E.M., LEHTO, T., LINDBERG, S., MORENO, P.M.D., VIOLA, J.R., MAGDY, T., ABDO, R., GUTERSTAM, P., et al. (2011). PepFect 14, a novel cell-penetrating peptide for olignucleotide delivery in solution and as solid formulation. Nucleic Acids Res. 39, 5284-5298.
13. FABANI M, M., ABREU-GOODGER, C., WILLIAMS, D., LYONS, P.A., TORRES, A., SMITH, K.G.C., ENRIGHT, A.J., GAIT, M.J., and VIGORITO, E. (2010). Efficient inhibition of miR-155 function in vivo by Peptide Nucleic Acids. Nucleic Acids Res. 38, 4466-4475.
14. GOUN, E.A., PILLOW, T.H., JONES, L.R., ROTHBARD, J.B., and WENDER, P.A. (2006). Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem 7, 1497-1515.
15. HEIDEL, J.D., YU, Z., LIU, J.Y., RELE, S.M., LIANG, Y., ZEIDEN, R.K., KORNBRUST, D.J., and DAVIS, M.E. (2011). Administration in non-human primates of escalating intravenous dosed of targeted nanoparticles containing ribonucleotides reductase subunitM2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 104, 5715-5721.
16. HENKE, E., PERK, J., VIDER, J., DE CANDIA, P., CHIN, Y., SOLIT, D.B., PONOMAREV, V., CATEGNI, L., MANOVA, K., ROSEN, N., et al. (2008). Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature Biotech. 26, 91-100.
17. HSU, T., and MITRAGOTRI, S. (2011). Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc. Nat. Acad. Sci. U. S. A. 108, 15816-15821.
18. JÄRVER, P., MÄGER, I., and LANGEL, U. (2010). In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci. 31, 528-535.
19. KUMAR, P., WU, H., MCBRIDE, J.L., JUNG, K.E., KIM, M.H., DAVIDSON, B.L., LEE, S.K., SHANKAR, P., and MANJUNATH, N. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43.
20. LAAKKONEN, P., and VUORINEN, K. (2010). Homing peptides as targeted delivery vehicles. Integr. Biol. 2, 326-337.
21. LANGEL, U. (2007). Handbook of Cell-Penetrating Peptides. (CRC Press, Boca Raton), pp.1-600.
22. LANGEL, U. (2011). Cell-penetrating Peptides. Methods and Protocols. (Springer, New York), pp.1-586.
23. LEHTO, T., SIMONSON, O.E., MÄGER, I., EZZAT, K., SORK, H., COPOLOVICI, D.-M., VIOLA, J.R., ZAGHLOUL, E.M., LUNDIN, P., MORENO, P.M.D., et al. (2011). A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol. Ther. 19, 1457-1467.
24. MAIER, M.A., ESAU, C.C., SIWKOWSKI, A.M., WANCEWICZ E.V., ALBERTSHOFER, K., KINBERGER, G.A., KADABA, N.S., WATANABE, T., MANOHARAN, M., BENNETT, C.F., et al. (2006). Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J. Med. Chem. 49, 2534-2542.
25. MARGUS, H., PADARI, K., and POOGA, M. (2012). Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol. Ther. doi:10.1038/mt.2011.284.
26. MELBYE, B.L., WELLER, D.D., HASSINGER, J.N., REEVES, M.D., LOVEJOY, C.E., IVERSEN, P.L., and GELLER, B.L. (2010). Cationic phosphordiamidate morpholino oligomers efficiently prevent growth of Escherischia coli in vitro and in vivo. J. Antimicrob. Chemother. 65, 98-106.
27. MICHIUE, H., EGUCHI, A., SCADENG, M., and DOWDY, S.F. (2009). Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther. 8, 2304-2311.
28. MORRIS, M.C., GROS, E., ALDRIAN-HERRADA, G., CHOOB, M., ARCHDEACON, J., HEITZ, F., and DIVITA, G. (2007). A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res., 35, e49.
29. MOULTON, H.M., and MOULTON, J.D. (2008). Antisense Morpholino Oligomers and Their Peptide Conjugates. In: Therapeutic Oligonucleotides. J. Kurreck, ed. (Royal Society of Chemistry, Cambridge, UK). pp. 43-79.
30. MOULTON, H.M., and MOULTON, J.D. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 12, 2296-2303.
31. OGRIS, M, and WAGNER, E. (2011). To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum. Gene Ther. 22, 799-807.
32. PASTOR, F.,KOLONIAS, D.,GIANGRANDE, P.H., and GILBOA, E. (2010). Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465, 227-230.
33. PULFORD, B., REIM, N., BELL, A., VEATCH, J., FORSTER, G., BENDER, H., MEYERETT, C., HAFEMAN, S., MICHEL, B., JOHNSON, T., et al. (2010). Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPc on neuronal cells and PrPRes in infected cell cultures. PloS One 5, e11085.
34. ROGERS, F.A., LIN, S.S., HEGAN, D.C., KRAUSE, D.S., and GLAZER, P.M. (2011). Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol. Ther. 20, 109-118.
35. RYDSTRÖM, A., DESHAYES, S., KONATE, K., CROMBEZ, L., PADARI, K., BOUKHADDAOUI, H., ALDRIAN, G., POOGA, M., and DIVITA G. (2011). Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PloS One 6, e25924.
36. SON, S., HWANG, D.W., SINGHA, K., JEONG, J.H., PARK, T.G., LEE, D.S., and KIM, W.J. (2011). RVG peptide tethered bioreducible polyethyleneimine for gene delivery to brain. J. Control. Release 155, 18-25.
37. STAQUICINI, F.I., OZAWA, M.G., MOYA, C.A., DRIESSEN, W.H.P., BARBU, E.M., NISHIMORI, H.,SOGHOMONYAN, S., FLORES 2ND, L.G., LIANG, X., PAOLILLO V., et al. (2011). Systemic combinatorial peptode selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121, 161-173.
38. STAQUICINI, F.I., SIDMAN, R.L., ARAP, W., and PASQUALINI, R. (2010). Phage display technology for stem cell delivery and systemic therapy. Adv. Drug Deliv. Rev. 62, 1213-1216.
39. TORRES, A.G., FABANI, M.M., VIGORITO, E., WILLIAMS, D., AL-OBAIDI, N., WOJCIECHOWSKI, F., HUDSON, R.H.E., SEITZ, O., and GAIT, M.J. (2011). Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res., doi:10.1093/nar/gkr885.
40. VAN DEN BERG, A., and DOWDY, S.F. (2011). Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22, 888-893.
41. WANCEWICZ, E.V., MAIER, M.A., SIWKOWSKI, A.M., ALBERTSHOFER, K., WINGER, T.M., BERDEJA, A., GAUS, H., VICKERS, T.A., BENNETT, C.F., MONIA, B.P., et al. (2010). Peptide nucleic acids conjugated to short basic peptide show improved pharmacokinetics and antisense activity in adipose tissue. J. Med. Chem. 53, 3919-3926.
42. WIDRICK, J.J., JIANG, S., CHOI, S.J., KNUTH, S.T., and MORCOS, P.A. (2011). An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve 44, 563-570.
43. WOOD, M.J.A. (2010). Towards an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci. Trans. Med. 2, 25ps15.
44. WOOD, M.J.A., GAIT, M.J., and YIN, H. (2010). RNA-targeted splice correction therapy for neuromuscular diseases. Brain 133, 957-972.
45. YIN, H., MOULTON, H.M., BETTS, C., MERRITT, T., SEOW, Y., ASHRAF, S., WANG, Q., BOUTILIER, J., and WOOD, M.J.A. (2010). Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Ther. 18, 1822-1827.
46. YIN, H., SALEH, A.F., BETTS, C., CAMELLITI, P., SEOW, Y., ASHRAF, S., ARZUMANOV, A., HAMMOND, S., MERRITT, T., GAIT, M.J., et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295-1303.